Praxis director granted RSUs and stock options

Praxis Precision Medicines director Stuart A. Arbuckle reported new equity awards in the company.

Rhea-AI Filing Summary

Praxis Precision Medicines director Stuart A. Arbuckle reported new equity awards in the company. On February 6, 2026, he received 688 restricted stock units and 478 restricted stock units, each at a price of $0, with vesting tied to 2026 and 2027 service and the 2026 annual meeting. Each unit represents one share of common stock, settled only in shares. He was also granted a stock option for 224 shares at an exercise price of $319.57, vesting in monthly installments from February 26, 2026 until the earlier of June 26, 2026 or the 2026 annual meeting. Following these grants, he beneficially owns 1,166 shares of common stock and 224 stock options, all held directly.

Insider Trade Summary

Grant/Award: 1,390 shares

Grant/Award 3 txns

Insider Arbuckle Stuart A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	224	$0.00	$0.00
Grant/Award	Common Stock	688	$0.00	$0.00
Grant/Award	Common Stock	478	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 224 contracts (Direct); Common Stock — 1,166 shares (Direct)

Footnotes (3)

1. F1. Mr. Arbuckle was awarded 688 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in two equal annual installments occurring on the first two anniversaries of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. F2. Mr. Arbuckle was awarded 478 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
3. F3. The shares subject to this option shall vest in equal monthly installments occurring on the 26th day of each month, with the first such installment occurring on February 26, 2026 and the final such installment occurring on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Praxis (PRAX) director Stuart Arbuckle receive?

Stuart Arbuckle received 688 restricted stock units, 478 restricted stock units, and a stock option for 224 shares of Praxis common stock on February 6, 2026, all granted at $0 cost to him at grant.

How do Stuart Arbuckle’s new Praxis (PRAX) restricted stock units vest?

The 688 RSUs vest in two equal annual installments on the first two anniversaries of January 8, 2026. The 478 RSUs vest in a single installment on the earlier of June 26, 2026 or the company’s 2026 annual meeting.

What are the terms of Stuart Arbuckle’s Praxis (PRAX) stock option grant?

He was granted a stock option for 224 shares at an exercise price of $319.57. The option vests in equal monthly installments on the 26th of each month from February 26, 2026 until the earlier of June 26, 2026 or the 2026 annual meeting.

How many Praxis (PRAX) shares does Stuart Arbuckle beneficially own after these grants?

After the reported grants, Stuart Arbuckle beneficially owns 1,166 shares of Praxis common stock directly. He also holds 224 stock options for additional common shares, subject to the vesting schedule disclosed in the filing.

Are Stuart Arbuckle’s Praxis (PRAX) restricted stock units settled in cash or shares?

Both restricted stock unit awards may be settled only by delivering shares of Praxis common stock. Each RSU represents a contingent right to receive one share, aligning his compensation directly with the company’s equity.

What role does Stuart Arbuckle hold at Praxis (PRAX) according to the Form 4?

According to the disclosure, Stuart Arbuckle is a director of Praxis Precision Medicines, Inc. The Form 4 specifies his relationship to the issuer as director only, with no officer or 10% owner status indicated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 04:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arbuckle Stuart A

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A(1)		688	A	$0	688	D
Common Stock	02/06/2026		A(2)		478	A	$0	1,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$319.57	02/06/2026		A		224		(3)	02/06/2036	Common Stock	224	$0	224	D

Explanation of Responses:

1. Mr. Arbuckle was awarded 688 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in two equal annual installments occurring on the first two anniversaries of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Mr. Arbuckle was awarded 478 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

3. The shares subject to this option shall vest in equal monthly installments occurring on the 26th day of each month, with the first such installment occurring on February 26, 2026 and the final such installment occurring on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.